Gilead To Partner With Nigeria Drugmakers For Mass Production Of Remdesivir For COVID-19 Drug

Gilead Sciences Inc (GILD.O) the largest research-based biopharmaceutical company that discovers, develops and commercializes medicines located in the United States has got the approval of United States regulation body U.S. Nourishment and Drug Administration’s crisis to mass-produce remdesivir for the treatment of COVID-19 across the globe.

The company has extended hand of fellowship to other drugmakers around the world to the production of remdesivir in their own country. Many Europeans countries have gone into partnership with the mass production and distribution of remdesivir that been approved as the treatment of coronavirus.

Gilead will storm Africa Continent with the instruction on how to produce remdesivir and the first Africa country that will be trained on the production of remdesivir is Nigeria. Gilead will teach selected Nigeria drugmakers on how to produce remdesivir which will also be regulated by the National Agency for Food and Drug Administration and Control (NAFDAC). The NAFDAC will recommend the best drugmakers in Nigeria to Gilead sciences. It will also be extended to other Africa countries. The same thing has done in India, the goal is to make remdesivir available pending the approval from the World Health Organisation.

Although remdesivir still remain a clinical trail of COVID-19, it has been approved by the U.S. Nourishment and Drug Administration’s crisis after the body disclosed that the drug has been used to treat COVID-19 patients. Gilead disclosed that remdesivir has passed phase 2 of the clinical trial and the result of phase 3 of the trail of investigation which was published on the website.

The World Health Organisation has yet to approve any drug for the treatment of coronavirus and many drugs are being investigated. Remdesivir is performing very well and it will soon be declared as the approved drug for the treatment of COVID-19.

Nelson

Omotimehin Nelson is a Nigerian award-winning content writer and journalist. He derives passion for creative writing. Join me